Skip to content
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Hematology · Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis

Your Care Team: Long-Term Monitoring and Support

At a Glance

Long-term care for HES and EGPA continues after remission. Personalized blood tests, symptom reviews, and heart checks can catch relapse or silent organ damage, while bone, blood sugar, and eye monitoring helps limit steroid side effects.

Achieving remission is a major milestone, but for patients with hypereosinophilia (HES) or EGPA, it is the beginning of a long-term journey of surveillance. Because these conditions can be “quiet” yet still cause underlying damage, your medical team will move from active treatment to a structured monitoring phase [1][2].

This page outlines how your specialists work together and what you can expect from your long-term follow-up.

Building Your Multi-Specialty Team

Managing these conditions requires a “team-based” approach. No single doctor can manage every aspect of the disease, so your care will likely be coordinated across several specialties:

  • Hematologist: Focuses on the “source” of the eosinophils. They monitor your bone marrow health, watch for clonal (genetic) changes, and manage therapies like imatinib or mepolizumab [3][4].
  • Rheumatologist: Often the lead for EGPA and other inflammatory diseases. They focus on managing vasculitis (blood vessel inflammation) and coordinate the use of immunosuppressants like rituximab [5][6].
  • Cardiologist: Crucial for anyone with a history of eosinophil-related heart damage. They monitor for silent inflammation, heart failure, and blood clots (thrombi) [7][8].
  • Pulmonologist: Manages the asthma and sinus symptoms that are common in EGPA and some forms of HES [9].

Your Surveillance Schedule

While every patient’s schedule is different, your monitoring plan will likely include the following components. The frequency is highly individualized based on your diagnosis, prior organ injury, treatment, and relapse history.

Blood Work (Frequent)

The Absolute Eosinophil Count (AEC) is a primary marker of disease activity. In the early stages of remission, you may have blood drawn every 2–4 weeks; as you stabilize, this may move to every 3 months, though this frequency is highly individualized [10]. Your doctor will also monitor CRP (a marker of inflammation) and troponin/BNP (markers of heart stress) as needed [11][12].

Cardiac Imaging (Periodic)

Even if your AEC is normal, your heart may need regular check-ups, especially if you have prior cardiac involvement.

  • Echocardiogram: Often performed periodically to check heart function and look for new clots, though routine echoes are not appropriate for every patient without prior cardiac involvement [13][14].
  • Cardiac MRI (CMR): This may be used if you have a history of heart involvement or if your blood markers (like troponin) rise. It can see small areas of inflammation or scarring that an echocardiogram might miss, but routine CMR is generally not needed without a clinical indication [15][2].

Symptom Check-ins

Relapse in EGPA often shows up first as worsening asthma or sinus pain, even if your AEC remains low [16][9]. Regular visits with your rheumatologist or pulmonologist are essential to catch these “airway-first” flares.

Managing Treatment Side Effects

Long-term use of medications like corticosteroids (prednisone) can cause its own set of challenges. Monitoring for “steroid toxicity” includes:

  • Bone Density (DEXA) scans: To check for osteoporosis [17].
  • Blood Sugar (A1c): To monitor for steroid-induced diabetes [18].
  • Eye Exams: To check for cataracts or glaucoma.

Mepolizumab and other biologics generally have a narrower immunosuppressive profile than steroids, but your team will still monitor for clinically relevant risks such as hypersensitivity, infection, and helminth considerations [19][20].

The Emotional Toll: ‘Scan Anxiety’

Living with a chronic condition that requires constant testing can lead to “scan anxiety”—the stress and fear that a routine test will show the disease has returned [21].

  • Validation: It is normal to feel anxious before a CBC or an MRI.
  • Action: Discuss these feelings with your care team. Some patients find it helpful to schedule their follow-up appointments for the same day their results come in, reducing the “waiting time” for answers. Consider keeping a symptom log to help you feel more in control.
  • Support: Consider joining a patient support group for HES or EGPA. Connecting with others who understand the unique challenges of “remission with monitoring” can provide significant emotional relief.

Remember, a “normalized” eosinophil count is a victory, but staying in remission requires staying vigilant. Your team is there to catch small changes before they become big problems [2][22].

Common questions in this guide

Which doctors may be involved in long-term HES or EGPA care?
A hematologist monitors the blood and bone marrow, while a rheumatologist often leads care for EGPA and blood-vessel inflammation. A cardiologist may monitor previous heart injury, and a pulmonologist can help manage asthma and sinus symptoms. Your team should agree on who coordinates the overall plan.
How often will I need blood tests after reaching remission?
Testing is individualized. Early in remission, the absolute eosinophil count may be checked every 2–4 weeks, then about every 3 months once counts are stable; doctors may also check inflammation and heart-stress markers when needed.
Do I still need heart tests if my eosinophil count is normal?
Sometimes. People with previous heart involvement may need periodic echocardiograms, and a cardiac MRI may be used when there is a history of heart disease or a concerning blood marker. Routine heart imaging is not needed for everyone, so your history and symptoms should guide the schedule.
What monitoring is needed if I take prednisone for a long time?
Long-term prednisone can affect bones, blood sugar, and the eyes. Your team may use bone-density scans, A1c blood tests, and eye examinations to look for osteoporosis, diabetes, cataracts, or glaucoma, and should create a supervised taper plan.
Can EGPA flare even when my eosinophil count is low?
Yes. In EGPA, worsening asthma or sinus pain can be an early sign of relapse even when the absolute eosinophil count remains low. Report new or worsening airway symptoms promptly to your rheumatologist or pulmonologist.
How can I cope with anxiety before monitoring tests?
Feeling anxious before blood work or scans is common when you are worried about relapse. Tell your care team, keep a symptom log, consider arranging visits when results are available, and look for an HES or EGPA support group if that feels helpful.

Get notified when new evidence is published on platelet abnormalities with eosinophilia and immune-mediated inflammatory disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (22)
  1. 1

    Déjà vu.

    Agrawal AO, Patankar AS, Samant R

    BMJ case reports 2026; (19(9)) doi:10.1136/bcr-2026-273616.

    PMID: 42749346
  2. 2

    Hypereosinophilic syndrome with Löffler endocarditis and multiple cerebral infarctions in a patient with a CLL-phenotype clonal B-cell population: a case report.

    Wang H, Zhu F, Hu H

    Frontiers in cardiovascular medicine 2026; (13()):1924869 doi:10.3389/fcvm.2026.1924869.

    PMID: 42688267
  3. 3

    World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.

    Shomali W, Gotlib J

    American journal of hematology 2024; (99(5)):946-968 doi:10.1002/ajh.27287.

    PMID: 38551368
  4. 4

    Eosinophilic Myocarditis.

    Cheung CC, Constantine M, Ahmadi A, et al.

    The American journal of the medical sciences 2017; (354(5)):486-492 doi:10.1016/j.amjms.2017.04.002.

    PMID: 29173361
  5. 5

    Primary care physicians play a crucial role in diagnosing and managing rare eosinophilic diseases: HES and EGPA.

    Shum M, Gewurz-Singer O, Silver J, Akuthota P

    Frontiers in medicine 2025; (12()):1568770 doi:10.3389/fmed.2025.1568770.

    PMID: 40630493
  6. 6

    Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management.

    Groh M, Pagnoux C, Baldini C, et al.

    European journal of internal medicine 2015; (26(7)):545-53.

    PMID: 25971154
  7. 7

    Hypereosinophilic syndrome: considerations for the cardiologist.

    Bondue A, Carpentier C, Roufosse F

    Heart (British Cardiac Society) 2022; (108(3)):164-171 doi:10.1136/heartjnl-2020-317202.

    PMID: 34172539
  8. 8

    [Cardiac involvement in Churg-Strauss syndrome].

    Brucato A, Maestroni S, Masciocco G, et al.

    Giornale italiano di cardiologia (2006) 2015; (16(9)):493-500 doi:10.1714/1988.21524.

    PMID: 26418389
  9. 9

    Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial.

    Puéchal X, Pagnoux C, Baron G, et al.

    Rheumatology (Oxford, England) 2019; (58(12)):2107-2116 doi:10.1093/rheumatology/kez139.

    PMID: 31056661
  10. 10

    A case of hypereosinophilic syndrome with STAT5b N642H mutation.

    Ding F, Wu C, Li Y, et al.

    Oxford medical case reports 2021; (2021(1)):omaa129 doi:10.1093/omcr/omaa129.

    PMID: 33542831
  11. 11

    Idiopathic Hypereosinophilic Syndrome in an Elderly Female: A Case Report.

    Khalid F, Holguin F

    The American journal of case reports 2019; (20()):381-384 doi:10.12659/AJCR.912747.

    PMID: 30902963
  12. 12

    Idiopathic Hypereosinophilic Syndrome Presenting as Isolated Right Ventricular Endomyocardial Fibrosis With Intracavitary Thrombus: A Multimodality Imaging Case Report.

    Loudiyi N, Malki M, Erregui H, et al.

    Cureus 2026; (18(7)):e113350 doi:10.7759/cureus.113350.

    PMID: 42639520
  13. 13

    Hypereosinophilic syndrome: cardiac diagnosis and management.

    Mankad R, Bonnichsen C, Mankad S

    Heart (British Cardiac Society) 2016; (102(2)):100-6 doi:10.1136/heartjnl-2015-307959.

    PMID: 26567231
  14. 14

    Normalization of left ventricular filling pressure after cardiac surgery for the Loeffler's endocarditis: a case report.

    Carcaterra A, Mock S, Müller H, Testuz A

    European heart journal. Case reports 2021; (5(6)):ytab189 doi:10.1093/ehjcr/ytab189.

    PMID: 34263118
  15. 15

    Fulminant Eosinophilic Myocarditis in Steroid-Refractory Hypereosinophilic Syndrome: Navigating the Thrombotic Stage With Targeted Biologic Therapy.

    Althobaiti M, Aldlgan D, Alfehaid L, et al.

    JACC. Case reports 2026; (31(41)):109306 doi:10.1016/j.jaccas.2026.109306.

    PMID: 42667290
  16. 16

    Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America.

    Doubelt I, Cuthbertson D, Carette S, et al.

    ACR open rheumatology 2021; (3(6)):404-412 doi:10.1002/acr2.11263.

    PMID: 34032390
  17. 17

    Mepolizumab as Possible Treatment for Allergic Bronchopulmonary Aspergillosis: A Review of Eight Cases.

    Tolebeyan A, Mohammadi O, Vaezi Z, Amini A

    Cureus 2020; (12(8)):e9684 doi:10.7759/cureus.9684.

    PMID: 32923277
  18. 18

    Mepolizumab and dupilumab as a replacement to systemic glucocorticoids for the treatment of Chronic Eosinophilic Pneumonia and Allergic Bronchopulmonary Aspergillosis - Case series, Almoosa specialist hospital.

    Eldaabossi SAM, Awad A, Anshasi N

    Respiratory medicine case reports 2021; (34()):101520 doi:10.1016/j.rmcr.2021.101520.

    PMID: 34692397
  19. 19

    Mepolizumab reduces systemic corticosteroid-related toxicities and healthcare burden in patients with eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: a retrospective database study.

    Pongdee T, Silver J, Deb A, et al.

    Frontiers in allergy 2026; (7()):1843149 doi:10.3389/falgy.2026.1843149.

    PMID: 42657158
  20. 20

    Long-Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis.

    Wechsler ME, Silver J, Wolff G, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2025; (77(8)):1052-1062 doi:10.1002/art.43146.

    PMID: 40008472
  21. 21

    Organ Involvement and Constitutional Symptoms in Idiopathic Hypereosinophilic Syndrome: A 72-Patient Single-Centre Cohort.

    Łacwik P, Kupryś-Lipińska I, Kucharczyk A, et al.

    Journal of clinical medicine 2026; (15(14)) doi:10.3390/jcm15145569.

    PMID: 42513483
  22. 22

    Study outcomes for eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: towards achieving treatment goals in clinical practice.

    Cid MC, Hellmich B, Terrier B, et al.

    Autoimmunity reviews 2026; 104207 doi:10.1016/j.autrev.2026.104207.

    PMID: 42977011

This page is for informational purposes only and does not constitute medical advice about HES or EGPA. Your hematologist, rheumatologist, and other specialists should determine your monitoring schedule and treatment plan.